Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Enanta Pharmaceuticals (ENTA) Income towards Parent Company: 2011-2025

Historic Income towards Parent Company for Enanta Pharmaceuticals (ENTA) over the last 15 years, with Sep 2025 value amounting to -$81.8 million.

  • Enanta Pharmaceuticals' Income towards Parent Company rose 35.08% to -$18.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$81.8 million, marking a year-over-year increase of 29.41%. This contributed to the annual value of -$81.8 million for FY2025, which is 29.41% up from last year.
  • Enanta Pharmaceuticals' Income towards Parent Company amounted to -$81.8 million in FY2025, which was up 29.41% from -$115.9 million recorded in FY2024.
  • Enanta Pharmaceuticals' Income towards Parent Company's 5-year high stood at -$78.9 million during FY2021, with a 5-year trough of -$133.8 million in FY2023.
  • In the last 3 years, Enanta Pharmaceuticals' Income towards Parent Company had a median value of -$115.9 million in 2024 and averaged -$110.5 million.
  • As far as peak fluctuations go, Enanta Pharmaceuticals' Income towards Parent Company crashed by 197.26% in 2021, and later climbed by 29.41% in 2025.
  • Yearly analysis of 5 years shows Enanta Pharmaceuticals' Income towards Parent Company stood at -$78.9 million in 2021, then slumped by 54.38% to -$121.7 million in 2022, then fell by 9.92% to -$133.8 million in 2023, then climbed by 13.42% to -$115.9 million in 2024, then rose by 29.41% to -$81.8 million in 2025.